Redox Regulation of Soluble Epoxide Hydrolase by 15-Deoxy-Δ-Prostaglandin J₂ Controls Coronary Hypoxic Vasodilation

Rebecca L. Charles, Joseph R. Burgoyne, Manuel Mayr, Steven M. Weldon, Norbert Hubner, Hua Dong, Christophe Morisseau, Bruce D. Hammock, Aimee Landar, Philip Eaton

**Rationale:** 15-Deoxy-Δ-prostaglandin (15d-PGJ₂) is an electrophilic oxidant that dilates the coronary vasculature. This lipid can adduct to redox active protein thiols to induce oxidative posttranslational modifications that modulate protein and tissue function.

**Objective:** To investigate the role of oxidative protein modifications in 15d-PGJ₂-mediated coronary vasodilation and define the distal signaling pathways leading to enhanced perfusion.

**Methods and Results:** Proteomic screening with biotinylated 15d-PGJ₂ identified novel vascular targets to which it adds, most notably soluble epoxide hydrolase (sEH). 15d-PGJ₂ inhibited sEH by specifically adducting to a highly conserved thiol (Cys521) adjacent to the catalytic center of the hydrolase. Indeed a Cys521Ser sEH “redox-dead” mutant was resistant to 15d-PGJ₂-induced hydrolase inhibition. 15d-PGJ₂ dilated coronary vessels and a role for hydrolase inhibition was supported by 2 structurally different sEH antagonists each independently inducing vasorelaxation. Furthermore, 15d-PGJ₂ and sEH antagonists also increased coronary effluent epoxygenosatrienoic acids consistent with their vasodilatory actions. Indeed 14,15-EET alone induced relaxation and 15d-PGJ₂-mediated vasodilation was blocked by the EET receptor antagonist 14,15-epoxygenosa-5(Z)-enoic acid (14,15-EEZE). Additionally, the coronary vasculature of sEH-null mice was basally dilated compared to wild-type controls and failed to vasodilate in response to 15d-PGJ₂. Coronary vasodilation to hypoxia in wild-types was accompanied by 15d-PGJ₂ adduction to and inhibition of sEH. Consistent with the importance of hydrolase inhibition, sEH-null mice failed to vasodilate during hypoxia.

**Conclusion:** This represents a new paradigm for the regulation of sEH by an endogenous lipid, which is integral to the fundamental physiological response of coronary hypoxic vasodilation. (Circ Res. 2011;108:324-334.)

**Key Words:** 15-deoxy prostaglandin J₂, soluble epoxide hydrolase ▪ redox signaling ▪ hypoxia
result, 15d-PGJ₂ reacts with nucleophilic protein cysteiny1 thiols, posttranslationally modifying them to achieve cell surface receptor-independent regulation. The most studied protein target of 15d-PGJ₂ is the peroxisome proliferator-activated receptor (PPAR) γ, which can be partially modulated by simple binding, but for the full complement of biological actions requires addition to sensor thiols within the receptor protein.³ Thus, derivatives devoid of electrophilic carbons fail to replicate the full spectrum of 15d-PGJ₂-mediated signaling, illustrating the importance of the oxidative addition reactions for biological adaptation.

15d-PGJ₂, the most recently identified prostaglandin, appears to have no specific receptor, although signaling via some prostaglandin (PG)D₂ receptors is possible.⁴ PGD₂ undergoes dehydration reactions to yield the J₂ series prostaglandins, including PGJ₂, 612-PGJ₂, and the subject of this study 15d-PGJ₂.⁵ 15d-PGJ₂ controls gene expression via interaction with transcriptional regulators, most notably PPARγ, but also Keap1 (Kelch-like ECH-associated protein 1) and nuclear factor (NF)-κB.⁷ 15d-PGJ₂ also targets other proteins, including Ras proteins,⁸ and thioredoxin,⁹ to regulate cellular responses independently of gene expression changes. Although addition of lipid electrophiles such as malondialdehyde and hydroxynonenal to proteins is routinely associated with disease pathogenesis, 15d-PGJ₂ is widely considered protective. Indeed 15d-PGJ₂ is a cell signaling molecule that is important for homeostatic maintenance, extensively mediating cellular adaptation to limit dysfunction during disease.⁴⁻⁹⁻¹³

Our studies presented here have revealed that the important drug target soluble epoxide hydrolase (sEH) is covalently modified by 15d-PGJ₂ and this inhibits its hydrolase activity. This is of note as sEH inhibitors are increasingly acknowledged to have therapeutic potential.¹⁴ 15d-PGJ₂ was found to vasodilate the coronary vasculature and a significant component of this was mediated by inhibition of sEH. Furthermore, this new signaling mechanism was also found to operate during coronary hypoxia, suggesting a potential role in hypoxic vasodilation. Consistent with hydrolase inhibition being crucial to coronary hypoxic vasodilation, sEH-null mouse hearts failed to dilate in response to hypoxia.

**Methods**

An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.

**Langendorff Perfusion**

Hearts were isolated and perfused with Krebs bicarbonate buffer in Langendorff mode.

**Purification and Identification of 15d-PGJ₂-Modified Proteins**

Mesenteric vessels were isolated and treated with 10 μmol/L biotinylated 15d-PGJ₂. Modified proteins were affinity-captured using streptavidin-agarose and identification using LC-MS/MS.

**Oxylipin Profile Analysis of Rat Heart Coronary Effluent**

This analysis was carried out using LC-MS/MS.

---

**Non-standard Abbreviations and Acronyms**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUDA</td>
<td>12-(3-adamantan-1-yl-ureido) dodecanoic acid</td>
</tr>
<tr>
<td>14,15-EEZE</td>
<td>14,15-epoxyeicosa-5(Z)-enoic acid</td>
</tr>
<tr>
<td>15d-PGJ₂</td>
<td>15-deoxy-Z-12,14-prostaglandin J₂</td>
</tr>
<tr>
<td>EET</td>
<td>epoxyeicosatrienoic acid</td>
</tr>
<tr>
<td>Keap1</td>
<td>Kelch-like ECH-associated protein 1</td>
</tr>
<tr>
<td>NF-κB</td>
<td>nuclear factor κB</td>
</tr>
<tr>
<td>PGD₂</td>
<td>prostaglandin D₂</td>
</tr>
<tr>
<td>PPAR</td>
<td>peroxisome proliferator-activated receptor</td>
</tr>
<tr>
<td>1-AUCB</td>
<td>trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyl-1]-benzoic acid</td>
</tr>
<tr>
<td>sEH</td>
<td>soluble epoxide hydrolase</td>
</tr>
<tr>
<td>SNP</td>
<td>single-nucleotide polymorphism</td>
</tr>
</tbody>
</table>

**sEH Activity Assay**

An established colorimetric sEH activity assay was used.¹⁵

**sEH Wild-Type and Cys521Ser Construct Generation**

The cDNA for mouse wild-type sEH was obtained from Origene and the Cys521Ser mutant created using the QuikChanger kit (Stratagene).

**Assessing Whether Thiol-Oxidizing Agents Inhibit sEH in Cells**

The ability of various thiol-oxidizing compounds to inhibit sEH was compared with 15d-PGJ₂ and the sEH inhibitor t-AUCB in HUVECs transfected to overexpress sEH.

**Assessing Whether Thiol-Oxidizing Agents Inhibit sEH In Vitro**

A commercially available sEH inhibitor screening assay kit (Cayman) was used.

**Results**

We examined the effect of 15d-PGJ₂ on the function of the isolated rat heart observing it to induce a transient vasorelaxation followed by a prominent and sustained vasodilation of the coronary vasculature (Figure 1A). Initially, we thought this vasorelaxation was likely to be mediated via PPARγ, because this protein is a well-established target of 15d-PGJ₂.³ However, pharmacological inhibition of PPARγ using GW9662 failed to attenuate the vasorelaxation induced by 15d-PGJ₂ (Figure 1A). Given the importance of vasoregulation in the maintenance of cardiovascular health, we undertook a proteomic screen to identify target proteins to which 15d-PGJ₂ covalently adducts, as these may provide clues regarding the mechanism of this vasorelaxation. Treatment of resistance blood vessels with a biotinylated derivative of 15d-PGJ₂ allowed us to observe its addiction to several proteins, which were not present in vehicle-treated controls (Figure 2A). To establish the identity of these postranslationally altered proteins, they were solubilized with Triton X-100 and affinity-captured using streptavidin-agarose. These proteins were resolved by SDS-PAGE and stained with colloidal Coomassie Blue, which showed a number of proteins in the 15d-PGJ₂-treated preparations which were absent
Figure 1. 15d-PGJ₂–induced coronary vessel vasorelaxation and sEH inhibition are intimately linked. A, 15d-PGJ₂ induced a transient vasoconstriction in the rat coronary vasculature, rapidly followed by a sustained vasodilation. This 15d-PGJ₂–mediated vasorelaxation was not modulated by the coadministration of the PPARγ inhibitor GW9662. B, AUDA (an sEH inhibitor) and 14,15-ETT (which is elevated following sEH inhibition) also induced vasodilation. C, t-AUCB (another sEH inhibitor) also induced vasodilation. D, 15d-PGJ₂–induced vasodilation was blocked by the EET receptor antagonist 14,15-EEZE, consistent with this coronary vasorelaxation involving EET accumulation. N=6/group in perfusion pressure monitoring studies. *P<0.05 for drug treatment vs aerobic perfusion control group. C and D show fewer data points to aid clarity and do not show the transient vasoconstriction in response to 15d-PGJ₂. E, Perfusion of isolated hearts with 15d-PGJ₂ or t-AUCB increased coronary effluent 14,15-EET concentration consistent with sEH inhibition. F, Similarly, perfusion with 15d-PGJ₂ increased coronary effluent 5,6 EET. N=4/group in EET measurement studies. *P<0.05.
in vehicle-treated controls (Figure 2B). These 15d-PGJ$_2$-modified proteins were excised from the gel and analyzed by LC-MS/MS with database searching, allowing the identification of component proteins (see Table 1 and the Online Data Supplement [Microsoft Excel file data]).

A review of this 15d-PGJ$_2$ adduct proteome we identified within vascular tissue highlighted a prominent candidate, namely sEH, which we thought could explain the vasodilatory actions of 15d-PGJ$_2$. A representative mass spectrum showing sEH is present in the 15d-PGJ$_2$ adduct proteome is shown in Online Figure I. We confirmed the proteomic identification of sEH as a target for 15d-PGJ$_2$ by Western immunoblotting with an antibody confirmed sEH was modified by 15d-PGJ$_2$.

D and E, sEH activity assays show that the established pharmacological antagonist AUDA or 15d-PGJ$_2$ inhibit hydrolase function in isolated hearts or cells (HEK cells or HUVECs) exposed to this lipid. N = 4 to 6/group in sEH activity analysis. *P < 0.05.

Figure 2. 15d-PGJ$_2$ adducts to sEH and inhibits its hydrolase activity. A, Treatment of blood vessels with biotin-15d-PGJ$_2$ resulted in multiple proteins being adducted by this electrophilic lipid. B, Proteins targets of biotin-15d-PGJ$_2$ were affinity captured using streptavidin-agarose, resolved by SDS-PAGE, and visualized with Coomassie blue. 15d-PGJ$_2$-modified proteins (absent in control) were excised and identified (see Table 1) using LC-MS/MS. C, Western immunoblotting with an antibody confirmed sEH was modified by 15d-PGJ$_2$. D and E, sEH activity assays show that the established pharmacological antagonist AUDA or 15d-PGJ$_2$ inhibit hydrolase function in isolated hearts or cells (HEK cells or HUVECs) exposed to this lipid. N = 4 to 6/group in sEH activity analysis. *P < 0.05.

We tested our hypothesis that 15d-PGJ$_2$ is a sEH inhibitor using an established epoxide hydrolase spectrophotometric activity assay. These sEH activity assays demonstrated that in vitro treatment of cardiac homogenates with AUDA or 15d-PGJ$_2$ robustly inhibited sEH catalytic hydrolase function (Figure 2D). These molecules both also inhibited sEH activity when given to the intact isolated rat heart (Figure 2D), HEK cells or HUVECs (Figure 2E). The data thus far were consistent with the 15d-PGJ$_2$–induced inhibition of sEH we have identified being mediated by its covalent addition to the hydrolase. Because 15d-PGJ$_2$ is known to selectively adduct to nucleophilic protein thiols, we assessed the structure of sEH with a view to identifying a candidate cysteine which would explain the inhibition. An examination of the crystal structure of sEH unveiled a conserved candidate thiol located proximal to the established catalytic center of the hydrolase (Figure 3A). To definitively assess the role of this thiol in 15d-PGJ$_2$–mediated sEH inhibition we generated both wild-type and Cys521Ser “redox-dead” mutant plasmid constructs of sEH and overexpressed the hydrolase in HEK cells or HUVECs (Figure 3C). The Cys521Ser alteration is a charge-conserved mutation, which represents a 1-atom (sulfur to oxygen) alteration and is anticipated to maintain catalytic activity. The Cys521Ser mutation decreases the nucleophilicity of the side chain and renders it insensitive to electrophilic addition reactions. Consequently, the ability of 15d-PGJ$_2$ to inhibit wild-type and Cys521Ser sEH was compared. Whereas the wild-type sEH was efficiently inhibited by the 15d-PGJ$_2$ treatment in both HEK cells and HUVECs, by replacing the thiol with a hydroxyl moiety rendered the hydrolase completely insensitive to the lipid (Figure 3D). This confirms the crucial importance of Cys521 of sEH in the redox control of its epoxide hydrolase activity, although an obvious question relates to the selectivity of 15d-PGJ$_2$ in this negative regulation. Accordingly, we examined the ability of a number of biologically important thiol-oxidizing molecules
to inhibit sEH hydrolase activity. Table 1 shows the IC50 values for this in vitro analysis and illustrates that H2O2 or GSNO do not inhibit the hydrolase. However, other electrophilic nitro or PG lipids (Online Table II; Figure 3F) also inhibited the hydrolase with similar (although not quite as effective) potency as 15d-PGJ2. However, the lipid electrophile HNE did not inhibit the hydrolase in vitro and was toxic to cells so precluded the analysis in that model system.

To further examine the role of hydrolase inhibition in 15d-PGJ2-induced vasorelaxation we exposed isolated hearts from wild-type or sEH-null mice to this lipid. Our initial isolated rat hearts studies involved constant flow perfusion mode, which is a very stable preparation. However, we found that isolated mouse hearts in constant flow were more susceptible to arrhythmias so making function more variable; consequently we used constant pressure mode. Whereas the wild-type mouse hearts responded to 15d-PGJ2 by increasing their coronary flow (ie, vasodilation as in the rat heart), the knockout failed to do this (Figure 4A). The importance of sEH inhibition in vasodilatory response to 15d-PGJ2 suggested by the studies above in rat are supported by the observation that at the midpoint to maximal relaxation in mouse heart that the hydrolase is inhibited (Figure 4B). The possibility that the higher basal coronary flow in sEH-null hearts was attributable to enhanced vasularization was excluded, as blood vessel density (measured by immunostaining the endothelial marker CD31 in frozen heart sections) was identical to wild-types (Figure 4C). The sEH-null isolated hearts also had an elevated basal coronary flow (ie, enhanced vasodilation) before 15d-PGJ2 treatment, which was 159% of wild-type controls. It is notable that the transient vasoconstriction induced by 15d-PGJ2 in rat heart was absent in mouse; although the focus of these studies is the sustained relaxation phenomena.

Subjecting isolated blood vessels to hypoxia markedly increased 15d-PGJ2 protein adduction compared with aerobic controls (Figure 4D). This hypoxic intervention also decreased sEH activity in these vessels, as would be anticipated following enhanced 15d-PGJ2 adduction (Figure 4E). Whereas the coronary vasculature of wild-type isolated mouse hearts dilated in response to hypoxia, there was once again a deficit in this response by the sEH-null myocardium (Figure 4F). A crucial role for sEH inhibition in mediating this rapid hypoxic vasodilation was evidenced by a concomitant adduction of 15d-PGJ2 (Figure 4G) and hydrolase inhibition (Figure 4H).

**Discussion**

The electrophilic cyclopentenone lipid 15d-PGJ2 induced a prominent and sustained vasodilation of rat and mouse coronary vasculature in isolated heart preparations. We performed studies to determine the molecular basis of this coronary vasodilation because it is important to understand these events because of their importance to cardiovascular

<table>
<thead>
<tr>
<th>Gel Band No.</th>
<th>Database Accession</th>
<th>Protein Name</th>
<th>Mr. Observed</th>
<th>Mr. Calculated</th>
<th>No. of Unique Peptides</th>
<th>No. of Unique Spectra</th>
<th>No. of Total Spectra</th>
<th>Protein Identification Probability*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>MYH11_MOUSE</td>
<td>Myosin 11</td>
<td>250 000</td>
<td>227 015</td>
<td>20</td>
<td>26</td>
<td>44</td>
<td>100%</td>
</tr>
<tr>
<td>1</td>
<td>MYH11_RAT</td>
<td>Myosin 11</td>
<td>250 000</td>
<td>152 479</td>
<td>7</td>
<td>10</td>
<td>78</td>
<td>100%</td>
</tr>
<tr>
<td>1</td>
<td>MYH9_RAT</td>
<td>Myosin 9 heavy chain</td>
<td>250 000</td>
<td>226 345</td>
<td>4</td>
<td>4</td>
<td>8</td>
<td>100%</td>
</tr>
<tr>
<td>2</td>
<td>CLH_RAT</td>
<td>Clathrin heavy chain 1</td>
<td>200 000</td>
<td>191 585</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>100%</td>
</tr>
<tr>
<td>3</td>
<td>CLH_RAT</td>
<td>Clathrin heavy chain 1</td>
<td>180 000</td>
<td>191 585</td>
<td>7</td>
<td>7</td>
<td>10</td>
<td>100%</td>
</tr>
<tr>
<td>4</td>
<td>COPA_MOUSE</td>
<td>Coatamer subunit α</td>
<td>150 000</td>
<td>138 317</td>
<td>11</td>
<td>11</td>
<td>16</td>
<td>100%</td>
</tr>
<tr>
<td>4</td>
<td>XDH_RAT</td>
<td>Xanthine dehydrogenase</td>
<td>150 000</td>
<td>146 775</td>
<td>8</td>
<td>8</td>
<td>14</td>
<td>100%</td>
</tr>
<tr>
<td>4</td>
<td>AD0_RAT</td>
<td>Aldehyde oxidase</td>
<td>150 000</td>
<td>146 904</td>
<td>4</td>
<td>5</td>
<td>8</td>
<td>100%</td>
</tr>
<tr>
<td>5</td>
<td>Unidentified</td>
<td></td>
<td>140 000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100%</td>
</tr>
<tr>
<td>6</td>
<td>PYC_BOVIN</td>
<td>Pyruvate Carboxylase</td>
<td>130 000</td>
<td>129 681</td>
<td>12</td>
<td>16</td>
<td>27</td>
<td>100%</td>
</tr>
<tr>
<td>6</td>
<td>ACY_BOVIN</td>
<td>ATP-citrate synthase</td>
<td>130 000</td>
<td>119 774.5</td>
<td>6</td>
<td>7</td>
<td>12</td>
<td>100%</td>
</tr>
<tr>
<td>7</td>
<td>0001_MOUSE</td>
<td>2-oxoglutarate dehydrogenase</td>
<td>125 000</td>
<td>116 432</td>
<td>10</td>
<td>14</td>
<td>25</td>
<td>100%</td>
</tr>
<tr>
<td>8</td>
<td>TERA_MOUSE</td>
<td>Transitional endoplasmic reticulum ATPase</td>
<td>100 000</td>
<td>89 307</td>
<td>10</td>
<td>12</td>
<td>19</td>
<td>100%</td>
</tr>
<tr>
<td>9</td>
<td>HSP7C_HUMAN</td>
<td>HSP 70 kDa</td>
<td>75 000</td>
<td>70 881.8</td>
<td>18</td>
<td>26</td>
<td>43</td>
<td>100%</td>
</tr>
<tr>
<td>9</td>
<td>HS71A_MOUSE</td>
<td>HSP 71 kDa</td>
<td>75 000</td>
<td>70 159.8</td>
<td>8</td>
<td>8</td>
<td>13</td>
<td>100%</td>
</tr>
<tr>
<td>10</td>
<td>Unidentified</td>
<td></td>
<td>65 000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>100%</td>
</tr>
<tr>
<td>11</td>
<td>CH60_RAT</td>
<td>HSP 60 kDa</td>
<td>55 000</td>
<td>60 938</td>
<td>9</td>
<td>12</td>
<td>24</td>
<td>100%</td>
</tr>
<tr>
<td>11</td>
<td>HYES_RAT</td>
<td>Soluble epoxide hydrolase</td>
<td>55000</td>
<td>62 323.8</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>99.8%</td>
</tr>
<tr>
<td>12</td>
<td>MCCC2_MOUSE</td>
<td>Methylcrotonyl-CoA carboxylase beta chain</td>
<td>48 000</td>
<td>61 362</td>
<td>12</td>
<td>16</td>
<td>29</td>
<td>100%</td>
</tr>
<tr>
<td>12</td>
<td>PCCB_MOUSE</td>
<td>Propionyl-CoA carboxylase</td>
<td>48 000</td>
<td>58 293</td>
<td>9</td>
<td>13</td>
<td>25</td>
<td>100%</td>
</tr>
</tbody>
</table>

*Protein identification probability was calculated using Scaffold (version 2.0, Proteome Software).
health and disease. Because PPARγ is perhaps the most prominent target for 15d-PGJ₂, we examined whether the vasodilation was blocked by the commonly used antagonist GW9662 and found it was not. This is consistent with PPARγ operating via transcriptional modulation, events which are too slow to account for the rapid vasodilatory response to 15d-PGJ₂. However, GW9662 did block the transient vasoconstriction observed in rat (but not mouse) heart by 15d-PGJ₂ and so clearly this antagonist can impact vasotone, although the mechanism of this remains unclear.

To provide new clues about the mechanism of coronary vasodilation, we used a biotinylated analog of 15d-PGJ₂ to affinity capture proteins this thiolate-reactive lipid adducts to as such oxidative posttranslational modifications are increasingly understood to control biological functions, including vasodilation. This proteomic approach led us to sEH as a prime candidate that mediates the vasodilatory actions of 15d-PGJ₂, because this hydrolase is known to convert potent vasodilatory EETs to less active dihydroxyeicosatrienoic acids. Thus, if 15d-PGJ₂ adduction to sEH induced hydrolase inhibition, this would result in accumulation of EETs and their potential vasodilatory actions, so providing a molecular explanation for the lipids relaxing the coronary vessels.

Indeed, our in vitro studies as well as those in cells and tissue preparations confirmed that 15d-PGJ₂ efficiently inhibited the hydrolase activity of sEH. Consistent with 15d-PGJ₂ relaxing

Figure 3. Cys521 of sEH is highly conserved and the target for 15d-PGJ₂ adduction. A, Model showing the established catalytic triad of sEH (Asp333, Asp495, and His523) required for epoxide hydrolysis. Directly adjacent to this is Cys521, making it a logical target for 15d-PGJ₂ adduction. B, Cys521 is present in sEH of all vertebrates, being conservatively replaced by a serine in phylogenetically lower organisms. C and D, Wild-type or Cys521Ser “redox-dead” mutants of sEH were expressed into HEK cells or HUVECs, resulting in their marked overexpression compared to untransfected controls. E, Although overexpressed wild-type hydrolase was inhibited by 15d-PGJ₂, the Cys521Ser mutant was not in either cell type. This confirms Cys521Ser is the site of 15d-PGJ₂ adduction. F, The ability of various thiol-oxidizing agents to inhibit sEH was compared with 15d-PGJ₂ and the pharmacological inhibitor t-AUCB in HUVECs. It is clear that there is some selectivity in the compounds that can inhibit the hydrolase, and this is verified by in vitro studies comparing the IC₅₀ of these compounds (see Table 2). N=3/group in sEH activity analysis. *P<0.05.
the coronary vasculature through an inhibitory action on sEH was the fact 2 structurally distinct pharmacological inhibitors of this hydrolase (AUDA or t-AUCB) themselves independently induced vasodilation. That 15d-PGJ2–induced relaxation signals at least in part via inhibition of sEH is supported by increased EETs levels in the coronary effluent following lipid treatment. That 14,15 EET was elevated was notable as when this was administered itself to isolated hearts it alone induced vasodilation. The importance of sEH inhibition is further substantiated by the EET receptor antagonist 14,15-

Figure 4. sEH-null mouse hearts fail to vasodilate in response to 15d-PGJ2 or hypoxia. A, Wild-type isolated hearts exposed to 15d-PGJ2 increased their coronary flow (ie, vasodilated). In notable contrast, the coronary flow of sEH-null hearts was not altered by perfusion with 15d-PGJ2 (N=6/group, *P<0.05 for comparison of wild-type coronary flow before and after hypoxia). However, it is notable that sEH-null mouse hearts had an elevated basal coronary flow compared to wild types. Inset shows a Western immunoblot confirming hearts from sEH-null mice do not express the hydrolase. B, Perfusion of wild-type heart with 15d-PGJ2 for 5 minutes (midway to maximal vasodilation) induced marked inhibition of sEH (N=4/group, *P<0.05). C, Frozen sections of wild-type or sEH knockout hearts were immunostained for the endothelial blood vessel marker CD31. Staining was comparable in both groups and so enhanced tissue vascularization of sEH knockout does not underlie the higher basal coronary flow (N=3/group, *P<0.05). D and E, Thoracic aorta was incubated with 15d-PGJ2 under normoxia or hypoxia. There was a marked potentiation of 15d-PGJ2 adduction to blood vessel proteins during hypoxia (representative Western blot and the graph of quantitative analysis shown), which also enhanced hydrolase inhibition (N=4/group, *P<0.05). F, Isolated wild-type mouse hearts vasodilate in response to myocardial hypoxia, whereas sEH-null hearts do not (N=4/group, *P<0.05). G, Hypoxia in the isolated mouse heart quickly (1 minute) induced sEH inhibition, consistent with these events, contributing causatively to a similarly rapid vasodilation at this time (N=3/group, *P<0.05). H, 15d-PGJ2–sEH adduct formation was monitored by immunoprecipitating sEH and measuring the 15d-PGJ2 present by ELISA. This confirmed that the hydrolase is modified by 15d-PGJ2 when the lipid is exogenously applied, as well as acutely during hypoxia (N=3 to 4/group, *P<0.05).
EEZE blocking the vasodilation induced by 15d-PGJ₂. Although 15d-PGJ₂-induced coronary vasorelaxation clearly involves sEH inhibition, as t-AUCB and EETs were less effective dilators, this suggests additional pathways such as DP receptor activation. A further consideration is the increase in 5,6 EET following 15d-PGJ₂ treatment, as this epoxide is not a significant sEH substrate. This highlights the prospect that 15d-PGJ₂ also may induce cytochrome P450 epoxyxygenase activity, the products of which may contribute to the associated coronary vasodilation.

Despite the very clear observation of coronary vasodilation in response to sEH inhibition (by 15d-PGJ₂ pharmacological inhibitors) as well as supporting information about the molecular details of this relaxation, these results may seem at odds with the literature. Inhibition of sEH hydrolase activity alone is generally considered insufficient to lower systemic blood pressure. Although initial studies with sEH-null mice reported they have lower blood pressure than wild-types, subsequent studies with this same line and also another independently generated line of mice failed to detect differences in systemic blood pressure. The disparity between studies was attributed to changes in the genetic background of the mice and the lack of the anticipated low blood pressure was explained by adaptive changes in renal function. In contrast to these studies in healthy mice, it is clear that sEH inhibition is an effective blood pressure-lowering therapy in animal models of hypertension. These past inconsistencies along with the fact that hydrolase inhibitors lower blood pressure in the setting of hypertension (but not health) may add confusion regards our observations. Our findings are unambiguous; it is evident that inhibition of sEH alone is sufficient to vasodilate the coronary vasculature of healthy rat and mouse. Consistent with these pharmacological inhibitor data are the prominent higher basal coronary flow in sEH-null mice. Thus, our observations do not conflict with the established literature but most likely simply reflect a critical difference between the coronary and peripheral vasculature.

An inspection of the crystal structure of sEH provided a clear candidate for the cysteine residue that 15d-PGJ₂ adducts to inhibit hydrolase activity. Cys521 is adjacent to the catalytic center of the enzyme, making it a rational target that would explain sEH inhibition by adduction of electrophiles.

The oxidative modification of Cys521 by the relatively bulky 15d-PGJ₂ might logically account for the inhibition, as it could be anticipated to alter the charge distribution at this location and perhaps sterically hinder access of EETs to the catalytic triad. Furthermore, the importance of Cys521 in the control of hydrolase function is supported by this residue being conserved in all higher vertebrates. Indeed in every phyllogenetically lower species (where sequence data are available) the cysteine is always replaced by a charge-maintaining serine residue (see Figure 3B). This conservative change may indicate the importance of an –SH or –OH side-chain at this position, implicating it as functionally essential. It may also suggest a catalytic tetrad actually forms the operational epoxide hydrolase unit. We speculate that the evolutionary replacement of serine with a cysteine may indicate the acquisition of reox control of sEH function in higher species. Consistent with these ideas was our observation that a Cys521Ser sEH mutant expressed in cells was resistant to the negative inhibition by 15d-PGJ₂.

The failure of hydrolase-null hearts to substantially dilate during coronary hypoxia was reminiscent of their impaired pulmonary hypoxic vasoconstriction. The differential response to coronary hypoxia was less pronounced than with treatment with 15d-PGJ₂. This is consistent with vasorelaxation attributable to 15d-PGJ₂ being primarily via sEH, but the hypoxia-mediated dilation likely being multifactorial with hydrolase inhibition being one of several contributory pathways. Previously we showed that myocardial hypoxia is associated with a depletion of protein sulfenic acids present basally during normoxia, explained by their reduction to the thiol state, which can revert back to basal if oxygen is resupplied. The reductive transition of basal sulfenic acids to free thiols provides a molecular mechanism explaining hypoxia-induced lipid adduction, as this generates the nucleophilic thiolate that reacts with 15d-PGJ₂. Although nanomolar concentrations of 15d-PGJ₂ are widely measured in biological systems, micromolar concentrations generally have to be added exogenously to obtain biological responses. This concentration gap may be explained in part by 15d-PGJ₂ being rapidly converted to alternate states, perhaps making measurement of free lipid less biologically relevant compared to nonelectrophilic signaling molecules. Essentially the loss of free 15d-PGJ₂ is intimately linked with the consequent biological activity. However, our new observations of hypoxia-induced sensitization to 15d-PGJ₂ adduct formation, which is consistent with previous observations of HNE-adduct formation during myocardial ischemia, shows that under certain conditions efficient lipid adduction can happen at much lower concentrations, perhaps below micromolar concentrations.

We assessed whether there is selectivity in this novel sEH inhibitory pathway, because Cys521 could be susceptible to oxidation by other electrophiles. Despite being perceived to have a relatively pervasive ability to induce protein S-sulfenylation or S-nitrosylation, respectively, H₂O₂ and GSNO were relatively ineffective sEH inhibitors in cells and caused no inhibition in vitro. Selectivity for 15d-PGJ₂ in adductive inhibition is further supported by the reactive lipid aldehyde HNE also failing to inhibit the hydrolase; thus sEH

### Table 2. Ability of Thiol-Reactive Molecules or Established Pharmacological sEH Antagonists to Inhibit Hydrolase Activity Was Compared

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC₅₀ (μmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>H²O₂</td>
<td>0.82</td>
</tr>
<tr>
<td>9-Nitrooate</td>
<td>16.50 ± 0.18</td>
</tr>
<tr>
<td>10-Nitrooate</td>
<td>20.50 ± 0.27</td>
</tr>
<tr>
<td>Spermine NONOate</td>
<td>No inhibition</td>
</tr>
<tr>
<td>GSNO</td>
<td>No inhibition</td>
</tr>
<tr>
<td>PGD₂</td>
<td>89.90 ± 1.99</td>
</tr>
<tr>
<td>15d-PGJ₂</td>
<td>10.30 ± 0.82</td>
</tr>
<tr>
<td>AUDA</td>
<td>0.27 ± 0.10</td>
</tr>
<tr>
<td>t-AUCB</td>
<td>0.23 ± 0.04</td>
</tr>
</tbody>
</table>
inhibition is not a class effect of all electrophilic lipids. However, sEH is not exclusively inhibited by 15d-PGJ2 as related electrophilic nitro lipids also do this. Nitro lipids are increasingly appreciated as important signaling molecules and perhaps because of their shared chemistry with 15d-PGJ2 can protect the heart from ischemia and reperfusion injury.28 Perhaps this is because they inhibit sEH, a reasonable possibility given established hydrolase inhibitors limit injury during ischemia and reperfusion.29

In connection with selectivity, we have to consider other targets of 15d-PGJ2 we identified. Although our studies here have shown a clear role for adduction and inhibition of sEH by 15d-PGJ2, given the complex and multifactorial mechanism regulating vasotone, we cannot discount roles for the other targets we identified (Table 1) in 15d-PGJ2–mediated vasodilation. Perhaps the most obvious candidate whose activity may also impinge on coronary vessel dilation is xanthine oxidoreductase which can generate vasoactive H2O2,30 is inhibited by electrophilic nitro lipids,31 and is activated by moderate hypoxia.32 Future investigations of a possible integrated role for xanthine oxidoreductase and sEH in 15d-PGJ2–mediated vasoregulation may therefore be valuable. Additional complexity regards the redox regulation of sEH follows the recent observation that hydrolase activity is inhibited by peroxynitrite-mediated tyrosine nitration.33

Given the important role of Cys521 in the redox control of sEH hydrolase activity, there is potential that mutation of this or adjacent residues may promote disease. Figure 5 shows the monomeric structure of sEH, highlighting the location of the redox active Cys521 and known human single-nucleotide polymorphisms (SNPs) in dbSNP and the 1000 Genome Project to date. There is no obvious SNP that would directly influence the thiol at Cys521. Furthermore, when we consider that sEH is a homodimer, we still did not identify SNPs on one chain that would fall close to Cys521 on the opposite chain (not shown). It is possible that SNPs remote from Cys521 may perturb the structure to alter the nucleophilicity of the thiol and so cause dysregulation; although another option is that such mutations are not viable.

A summary of our observations and the sequence of events are outlined in Figure 6, showing that 15d-PGJ2 covalently modifies a conserved thiol (Cys521) proximal to the catalytic center of sEH which inhibits hydrolase activity. Consequently, EETs accumulate and exert their established vasodilatory action in the coronary vasculature.20 This mechanism contributes in part to the fundamental physiological response of coronary vasodilation. Although this study has focused on the details of this novel mechanism of coronary vasoregulation; it is notable that both 15d-PGJ2 and inhibitors of sEH are molecules that provide protection from variety of diseases. The disease-limiting affects of 15d-PGJ2 is likely significantly mediated via its inhibition of sEH, consistent with the overlapping cytoprotection provided by established hydrolase antagonists. Thus 15d-PGJ2 protects against cancer,9 inflammation and hypertension,4 and diseases of the brain,10 gut,11 heart,12 and lungs.13 sEH inhibitors provide an integrated cardiovascular protection against hypertension, ischemia and reperfusion, hypertrophy, and heart failure.34 Con-
sistent with the therapeutic value of hydrolase inhibitors, sEH-null mice are protected from pathological interventions.\textsuperscript{29} Conversely, genetic alterations that promote enhanced hydrolase activity are a risk factor in a rat model for human heart failure.\textsuperscript{35} Thus, the beneficial actions of 15d-PGJ\textsubscript{2} and antagonists such as ADA can be rationalized by them exerting the same molecular action, namely inhibition of sEH hydrolase activity.

Acknowledgments

We thank Michelle S. Johnson for preparation of the biotinylated 15d-PGJ\textsubscript{2}.

Sources of Funding

We acknowledge support from the Medical Research Council and the British Heart Foundation (to P.E.), American Heart Association Grant SDG 0635361N (to A.L.), National Institute of Environmental Health Sciences grant ES02710 (to B.D.H.), and the National Institute of Environmental Health Sciences Superfund Basic Research Program (P42 ES04699 to B.D.H.). We also acknowledge support from the Department of Health through a National Institute for Health Research Comprehensive Biomedical Research Centre award to Guy’s & St Thomas’ National Health Service Foundation Trust in partnership with King’s College London. N.H. is supported by the German Federal Ministry of Education and Research National Network. B.D.H. is a George and Judy Marcus Senior Fellow of the Charles et al 15d-PGJ\textsubscript{2} Inhibits Soluble Epoxide Hydrolase 333

References


---

**Novelty and Significance**

**What Is Known?**

- 15-Deoxy-Δ9-prostaglandin (15d-PGJ2) is a cytoprotective lipid prostaglandin with chemical properties that allow it to couple to, and potentially regulate the function of, proteins.

- Pharmacological inhibition of soluble Epoxide Hydrolase (sEH), an enzyme that metabolizes epoxyeicosatrienoic acids, is broadly protective in models of cardiovascular disease.

**What New Information Does This Article Contribute?**

- 15d-PGJ2 covalently couples to sEH to inhibit the degradation of epoxyeicosatrienoic acids causing their accumulation.

- Pharmacological inhibition of soluble Epoxide Hydrolase (sEH), an enzyme that metabolizes epoxyeicosatrienoic acids, is broadly protective in models of cardiovascular disease.

- This inhibitory mechanism has a rational structural basis, as 15d-PGJ2 adduction occurs at a highly conserved amino acid (cysteine 521) adjacent to the known catalytic centre of the hydrolase.

- This new inhibitory mechanism occurs in coronary vessels during hypoxia and contributes to the fundamental response of hypoxic vasodilation.

We used proteomic methods to find the molecular targets of 15d-PGJ2, a cytoprotective prostaglandin that induces coronary vasodilation. This strategy identified sEH, an enzyme which is considered to be an important drug target because pharmacological inhibitors of its hydrolase activity are known to be of benefit in several disease models. Adduction of 15d-PGJ2 occurred at cysteine 521 of sEH, which inhibited hydrolase activity and caused epoxyeicosatrienoic acid concentrations to rise. Consequently, 15d-PGJ2 may be considered an endogenous natural inhibitor of sEH, potentially mimicking aspects of the cardioprotective signals associated with pharmacological inhibition of this hydrolase. This novel mechanism of sEH inhibition by lipid adduction occurred during hypoxia and was integral to the associated coronary vasodilation. This new findings suggest a role for pharmacological sEH inhibition in coronary dilatation which may be beneficial in the setting of angina.
Redox Regulation of Soluble Epoxide Hydrolase by 15-Deoxy-Δ2-Prostaglandin J2 Controls Coronary Hypoxic Vasodilation

Rebecca L. Charles, Joseph R. Burgoyne, Manuel Mayr, Steven M. Weldon, Norbert Hubner, Hua Dong, Christophe Morisseau, Bruce D. Hammock, Aimee Landar and Philip Eaton

_Circ Res._ 2011;108:324-334; originally published online December 16, 2010; doi: 10.1161/CIRCRESAHA.110.235879

_Circulation Research_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:

http://circres.ahajournals.org/content/108/3/324

Data Supplement (unedited) at:

http://circres.ahajournals.org/content/suppl/2010/12/16/CIRCRESAHA.110.235879.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation Research_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:

http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation Research_ is online at:

http://circres.ahajournals.org/subscriptions/
Detailed online methods

Isolated rat and mouse heart Langendorff perfusion

Hearts were isolated from adult Wistar rats (B&K Universal) and perfused with Krebs bicarbonate buffer as described previously. Rat hearts were perfused at a constant pressure of 72mmHg for the duration of the stabilisation period and then switched to constant flow for the remainder of the experiment. Rat hearts were stabilized with 20 minutes aerobic perfusion before continued perfusion using protocols shown at the bottom of Figures 1A-D. When drugs were assessed for their ability to block 15d-PGJ2-induced vasodilation, they were pre-loaded alone into the heart for 10 minutes before continued perfusion together with the lipid. 15d-PGJ2, AUDA (12-(3-adamantan-1-yl-ureido)dodecanoic acid), 14,15 EET and GW9662 were each used at 10 μmol/L, t-AUCB (trans-4-[4-(3-Adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid) was used at 20 μmol/L and 14,15-EEZE (14,15-epoxyeicosa-5(Z)-enoic acid) was used at 1 μmol/L. Hydrophobic drugs were dissolved in DMSO, with appropriate vehicle controls. The sEH knockout mouse line used was previously described. Rigorous backcrossing to C57BL/6ByJ for 9 generations was undertaken to ensure genetic homogeneity. Genetic homogeneity was confirmed using a 5K mouse SNP array. Of the 4,792 SNPs represented on the array, 2,443 SNPs could discriminate 129/SJ and C57BL/6ByJ genomes and confirmed that the Ephx2 null colony did not contain any residual 129/SJ background outside the targeted locus region and shared the identical background. Adult mouse hearts were stabilised with 20 minutes aerobic perfusion in constant using protocols summarised in Figure 4. Constant pressure mode was maintained using a STH Pump Controller (ADInstruments) to control a Minipuls 3 peristaltic pump (Gilson), with online data acquisition using LabChart software (ADInstruments) allowing coronary flow to be calculated and recorded in real time. Hypoxic interventions involved gassing the Krebs bicarbonate buffer with 21% O2, 74% N2 and 5% CO2.

Purification and identification of 15d-PGJ2-modified proteins

Mesorenteric vessels were isolated and treated with 10μM biotinylated 15d-PGJ2. After snap freezing a mesenteric cell lysate was made, in which the vessels were then homogenised in 100 mmol/L Tris-HCl pH7.4, 1% Triton X-100 and protease inhibitor cocktail (Roche Complete C, 1 tablet per 50ml buffer). 200 μl of cell lysates was incubated and rotated at 4°C with streptavidin-agarose (Calbiochem) overnight. The beads were then washed with 10ml of 20mmol/L Tris pH7.4 + 1% Triton X-100, and then eluted with SDS sample buffer containing 100mmol/L maleimide at 50°C for 5 minutes. Protein were separated by SDS-PAGE and stained with colloidal Coomassie blue and protein bands were excised for identification involving LC-MS/MS analysis of tryptic digests. n brief, gel slices were treated with trypsin using published methods, modified for use with an Investigator ProGest (Genomic Solutions) robotic digestion system. Digested peptides were separated by nanoflow liquid chromatography (Ultimate 3000™, Dionex) on a reverse-phase column (PepMap 100, 75μm I.D., 15cm length, Dionex) at a flow rate of 300nl/min. The column was coupled to a linear ion trap mass spectrometer (LTQ-XL, Thermofinnigan) using full ion scan mode over the mass-to-charge (m/z) range 300-2000. Tandem mass spectrometry (MS/MS) was carried out on the top six ions in each MS scan using the data-dependent acquisition mode with dynamic exclusion enabled. Generated spectra were matched to database entries (UniProt Knowledgebase) using TurboSEQUEST software (Bioworks 3.4, Thermo Finnigan). Scaffold (version 1.0, Proteome Software Inc., Portland, OR) was used to validate MS/MS based peptide and protein identifications. Protein identifications were accepted if probability was greater than 95.0% as specified by the Protein Prophet algorithm.

Oxylipin profile analysis of rat heart coronary effluent

This analysis was carried out as previously described in detail. Briefly, heart perfusate samples were spiked with 10μL 500nM internal standard I (d4-6-keto-PGF1α, d4-PGE2, d4-TXB2, d4-LTB4, d11-14,15-DiHETE, d6-20-HETE, d4-9-HODE, d8-12-HETE, d8-5-HETE, d11-11(12)-EpETrE, d4-9(10)-EpOME, d8-AA) and then were extracted by solid phase extraction using Oasis HLB cartridges (3cc 60mg, Waters, Milford, MA). The HLB cartridges were first washed with 2ml ethyl acetate, 2ml methanol twice, and 2 ml 95:5 v/v water/methanol with 0.1% acetic acid. The 6ml heart perfusate samples were then loaded onto the cartridges with 3ml samples each time. The samples were then washed with 6ml 95:5 v/v water/methanol with 0.1% acetic acid and dried for 20min with low vacuum. The target analytes were then eluted with 0.5ml methanol followed by 2ml of ethyl acetate into the tubes with 6μl 30% glycerol in
methanol as the trap solution. The volatile solvents were evaporated by using vacuum centrifugation (Speed-Vac) until 2µl trap solution remains in the tube. The residues were dissolved in 50µL of methanol containing 200nmol/L internal standard II (1-cyclohexyl-dodecanoic acid urea, CUDA). The samples were mixed with a vortex mixer for 2min, centrifuged at 14000 x g for 5min and then transferred to auto sampler vials with 150µl inserts for LC/MS/MS analysis. Liquid chromatography/tandem MS (LC/MS/MS) analysis of oxylipins was performed using an Agilent 1200 SL liquid chromatography series (Agilent Corporation, Palo Alto, CA). An Agilent Eclipse Plus C18 2.1 x 150mm, 1.8µm column to separate the oxylipins. The mobile phase A was water with 0.1% acetic acid while the mobile phase B was composed by acetonitrile/methanol (80/15, v/v) and 0.1% acetic acid. Gradient elution was performed at a flow rate of 250µl/min and the gradient used is described in the attached table. The injection volume was 10µl and the samples were kept at 4°C in the auto sampler. Analytes were detected by negative MRM mode using a 4000 QTrap tandem mass spectrometer (Applied Biosystems Instrument Corporation, Foster City, CA) equipped with an electrospray ionization source (Turbo V). The QTrap was set as follows: CUR = 20psi, TEM = 500°C, GS1 = 50psi, GS2 = 30psi, CAD = High, IS = -4500V, DP = -60V, EP = -10V. Calibration curves were generated by 10µl injections of seven standards containing each analyte, internal standard I, and internal standard II for quantification purposes.

**Soluble epoxide hydrolase activity assay**

An established colorimetric sEH activity assay was used, utilising trans-stilbene oxide (TSO) as a substrate. TSO contains an epoxide which is converted to a diol by sEH, substantially decreasing its absorbance at 229nm. sEH activity was determined in isolated rat hearts that had previously been perfused under control conditions, or with 10µmol/L AUDA for 20 minutes or 10µmol/L 15d-PGJ2 for 20 minutes. A 200mg aliquot of rat heart (which had been powdered under and stored in liquid nitrogen) or a whole mouse heart was homogenised (1ml of buffer per 100mg of cardiac tissue) on ice in 200mmol/L sodium phosphate buffer, pH7.4 using a Polytron tissue grinder. Cytosolic fractions were prepared from the hearts by centrifugation at 100,000g for 30 minutes at 4°C, which removes microsomal sEH which would interfere with the assay. 50µl of the cytosolic fraction was then used for the activity assay, adding it to 940µl of 200mmol/L sodium phosphate buffer pH7.4. After equilibration at room temperature, the reaction was initiated by the addition of 10µl of 5mmol/L TSO dissolved in ethanol. The reaction mixture was left for 20 minutes, after which the absorbance was monitored at 229nm. In an additional reaction mixture, no sEH was added as a control to ascertain the absorbance of TSO alone.

**Soluble epoxide hydrolase wild-type and Cys521Ser construct generation and over-expression**

The cDNA for mouse wild-type sEH was obtained from Origene. Site-directed mutagenesis of wild-type sEH to replace the Cys521 residue with Ser to create a ‘redox-dead’ mutant was performed by using the QuikChanger Site-directed mutagenesis kit from Stratagene. HEK cells were maintained in DMEM with 10% FCS and antibiotics. For treatment of HEK, cells were plated on to 12 well plates. HEK cells were transfected with wild-type DNA (Origene) or mutant (C521S) following the manufacturer’s instructions (Polyfect, Qiagen), with some cells left untransfected, as an additional control. The cells were incubated in serum free media overnight prior to treatment interventions. The cells were then subjected to treatment interventions, which consisted of media alone (control), 10µmol/L 15d-PGJ2, or 10µmol/L AUDA. After 1 hour of treatment, cell lysates were prepared by adding SDS sample buffer and subjected to Western immunoblot analysis. HUVEC’s were also used to overexpress wild type or mutant (C521S) DNA. They were plated onto 12 well plates and transfected with DNA (Origene) and wild-type or mutant (C521S) following the manufacturer’s instructions (jetPEI-HUVEC, Polyplus), with some cells left untransfected, as an additional control. The HUVEC’s were then subjected to the same treatment interventions as the HEK cells as stated above.

To assess the activity of soluble epoxide hydrolase, HEK cells were plated onto 6 well plates. HEK cells were co-transfected with DNA (Origene) and wild-type or mutant (C521S) following the manufacturer’s instructions (Polyfect, Qiagen), with some cells left untransfected, as an additional control. The cells were incubated in serum free media overnight prior to treatment interventions. The cells were then subjected to treatment interventions, which consisted of media alone (control), 10µmol/L 15d-PGJ2, or 10µmol/L AUDA. After 1 hour of treatment, cell lysates were prepared by adding 200µl of sodium phosphate buffer and scrapped into Eppendorf tubes. The cells were lysed by freeze thawing three times. Cell lysates were centrifuged at 12000rpm for 2 minutes and the supernatant was used the sEH
activity assay. HUVEC’s were also used to assess the activity of sEH. They were transfected as stated above using the jetPEI-HUVEC reagent and then subjected to the same treatment interventions as the HEK cells for the sEH activity assay.

Assessing whether thiol-oxidizing agents inhibit soluble epoxide hydrolase in cells

The ability of various thiol-oxidizing compounds to inhibit sEH was compared with 15d-PGJ2 and the sEH inhibitor t-AUCB in HUVEC cells. HUVEC cells were transfected with WT sEH as described above. The cells were then subjected to treatment interventions which consisted of media alone (control), 10μmol/L GSNO, 10μmol/L 9-Nitrooleate, 10μmol/L PGD2, 10μmol/L H2O2, 10μmol/L 15d-PGJ2, or 10μmol/L t-AUCB. 10μmol/L HNE and 10μmol/L 10-Nitrooleate were also tested but were toxic to the cells. The cells were treated for 1 hour, after which cell lysates were prepared as described above. The activity was assessed using the sEH activity assay as described above.

Assessing whether thiol-oxidizing agents inhibit soluble epoxide hydrolase in vitro

A commercially available sEH inhibitor screening assay kit (Cayman) was used. The manufacturers protocol was followed; briefly human recombinant sEH was treated with various thiol oxidising compounds (0.1-30μmol/L) to determine the IC50 for each of the following compounds, HNE, 9-Nitrooleate, 10-Nitrooleate, H2O2, Spermine NONOate, GSNO, PGD2, 15d-PGJ2, AUDA, t-AUCB.

Hypoxic treatment of rat thoracic aorta

Rat thoracic aortas were isolated and cleaned of connective tissue and placed into Krebs bicarbonate buffer. The aortas were subjected to 30 minutes normoxia or hypoxia by gassing the Krebs with 95% O2:5% CO2 or 95% N2:5% CO2 respectively. Subsequently the vessels were snap frozen and subjected to the soluble epoxide hydrolase assay as described above. In another series of experiments, vessels treated with 15d-PGJ2 and subjected to 30 minutes normoxia or hypoxia (as above); the vessels were then snap frozen and reconstituted directly into SDS sample buffer.

Immunohistochemistry and confocal microscopy

Hearts were removed from sEH WT and KO mice under terminal anaesthesia, and quickly embedded into OCT and frozen in freezing isopentane. Frozen hearts were kept at -80°C until required. The hearts were sectioned using a cryostat BRIGHT Model OTF. Sequential sections 8μm thick were cut and placed onto poly-L-lysine coated microscope slides. The sections were allowed to dry and then frozen until further use. The sections were rehydrated with PBS, before being fixed with 4% paraformaldehyde. The monoclonal mouse anti-rat CD31 antibody was obtained from the AbD Serotec and was used at a dilution of 1:200. The secondary antibody, an Alexa Flour 546 goat anti-rat (Molecular Probes) was used at a dilution of 1:200. The specimens were analyzed using confocal microscopy on an inverted microscope (Leica SP5 system, Mannheim, Germany) equipped with a blue diode and argon and helium neon lasers using a 63×/1.4 numerical aperture oil immersion lens.

Monitoring sEH-15d-PGJ2 adduct formation

Mouse myocardium was homogenised (1ml of buffer per 100mg of cardiac tissue) on ice in 200mmol/L sodium phosphate buffer + Roche protease inhibitor cocktail, pH7.4 using a Polytron grinder and centrifuged at 20,000g for 10 minutes at 4°C. The supernatant was removed and SDS added to a final concentration of 1% (wt/vol) and rotated for 10 minutes at 4°C, before diluting 100μl to 1ml with 100mmol/L Tris-HCl + 1% (vol/vol) Triton-X100, pH 7.4 and rotating for a further 10 minutes at 4°C. This was then centrifuged and soluble supernatant protein collected for immunoprecipitation of sEH using a mouse monoclonal antibody (Santa Cruz Biotechnology Inc., sc-166961). Immune complexes were harvested with anti-mouse IgG/protein A-agarose (Upstate Biotechnology) and then eluted using 50mmol/L glycine pH3.5 with subsequent neutralization using 100mmol/L Tris-HCl pH7.4. The presence of 15d-PGJ2 in the immunoprecipitated sEH was assayed using an ELISA assay (Enzo Life Sciences).

Statistics

Results are presented as mean ± SEM. Differences between groups were assessed using ANOVA followed by a t test. Differences were considered significant at the 95% confidence level.
References for methods


Online supplementary Figure I. Example mass spectrum of a peptide used to identify soluble Epoxide hydrolase as a target of 15d-PGJ$_2$. 